Literature DB >> 17762548

Growth factors for therapeutic angiogenesis in peripheral arterial disease.

William S Jones1, Brian H Annex.   

Abstract

PURPOSE OF REVIEW: Peripheral arterial disease is a common disease that has few treatment options. Angiogenesis is defined as the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis is an investigational method that uses vascular growth to alleviate disorders of tissue ischemia, such as coronary artery disease and peripheral arterial disease. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future. RECENT
FINDINGS: Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm, but larger clinical studies have failed to achieve similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, gene therapy and cell therapy have moved to the forefront of therapeutic angiogenesis. Novel therapies which target multiple different angiogenic pathways are also being developed and tested.
SUMMARY: Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the different growth factors being used, their routes of delivery, the results of clinical trials, and some of the novel therapies being developed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762548     DOI: 10.1097/HCO.0b013e328236741b

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  22 in total

Review 1.  Systems biology of pro-angiogenic therapies targeting the VEGF system.

Authors:  Feilim Mac Gabhann; Amina A Qutub; Brian H Annex; Aleksander S Popel
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Nov-Dec

2.  ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model.

Authors:  Carolina A Ferreira; Reinier Hernandez; Yunan Yang; Hector F Valdovinos; Jonathan W Engle; Weibo Cai
Journal:  Mol Pharm       Date:  2018-06-25       Impact factor: 4.939

Review 3.  TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE.

Authors:  Brian H Annex; George A Beller
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

4.  miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome.

Authors:  Rebecca Hutcheson; Jennifer Chaplin; Brenda Hutcheson; Faye Borthwick; Spencer Proctor; Sarah Gebb; Rashmi Jadhav; Erika Smith; James C Russell; Petra Rocic
Journal:  FASEB J       Date:  2014-06-05       Impact factor: 5.191

5.  Noninvasive In Vivo Quantification of Adeno-Associated Virus Serotype 9-Mediated Expression of the Sodium/Iodide Symporter Under Hindlimb Ischemia and Neuraminidase Desialylation in Skeletal Muscle Using Single-Photon Emission Computed Tomography/Computed Tomography.

Authors:  Nabil E Boutagy; Silvia Ravera; Xenophon Papademetris; John A Onofrey; Zhen W Zhuang; Jing Wu; Attila Feher; Mitchel R Stacy; Brent A French; Brian H Annex; Nancy Carrasco; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2019-07-12       Impact factor: 7.792

6.  Improved vascular survival and growth in the mouse model of hindlimb ischemia by a remote signaling mechanism.

Authors:  Kotaro Takeda; Li-Juan Duan; Hiromi Takeda; Guo-Hua Fong
Journal:  Am J Pathol       Date:  2014-01-17       Impact factor: 4.307

Review 7.  Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?

Authors:  Petra Rocic
Journal:  Vascul Pharmacol       Date:  2012-02-09       Impact factor: 5.773

8.  Micro- and Nanoparticles for Treating Cardiovascular Disease.

Authors:  S Suarez; A Almutairi; K L Christman
Journal:  Biomater Sci       Date:  2015-04       Impact factor: 6.843

9.  Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.

Authors:  Maarten A Lijkwan; Alwine A Hellingman; Ernst J Bos; Koen E A van der Bogt; Mei Huang; Nigel G Kooreman; Margreet R de Vries; Hendrika A B Peters; Robert C Robbins; Jaap F Hamming; Paul H A Quax; Joseph C Wu
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

Review 10.  Intermittent claudication: new targets for drug development.

Authors:  Eric P Brass
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.